As mentioned above, CLL patients with TP53 disruption, by either deletion or mutation, are refractory (i.e., failing treatment or progressing within six months from treatment start) to CIT regimens [2,21]. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.